Aethlon Medical (NASDAQ:AEMD) Releases Quarterly Earnings Results, Beats Expectations By $0.27 EPS

Aethlon Medical (NASDAQ:AEMD) posted its quarterly earnings results on Thursday. The medical equipment provider reported ($0.91) EPS for the quarter, beating the consensus estimate of ($1.18) by $0.27, Zacks reports. During the same quarter in the prior year, the business posted ($1.10) earnings per share.

Aethlon Medical Price Performance

NASDAQ:AEMD traded down $0.08 during trading hours on Friday, hitting $0.50. 1,707,769 shares of the company were exchanged, compared to its average volume of 11,476,545. The stock has a market capitalization of $1.31 million, a price-to-earnings ratio of -0.10 and a beta of 1.60. Aethlon Medical has a 52-week low of $0.37 and a 52-week high of $5.00. The company’s 50 day moving average price is $0.78 and its 200-day moving average price is $1.44.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on AEMD. StockNews.com began coverage on shares of Aethlon Medical in a report on Sunday, June 23rd. They issued a “sell” rating for the company. HC Wainwright reduced their price target on shares of Aethlon Medical from $10.00 to $7.00 and set a “buy” rating for the company in a report on Monday, June 24th.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.